(1) 本药物由于有引发低血糖症状的可能，故对从事高空或汽车驾驶等工作的病人要谨慎用药。

(2) 在给予本药物的期间，要定期进行血糖检测，同时仔细观察其过程，当用药2至3个月效果仍不十分明显的时，则必须考虑另选其他认为更加有效的治疗方法。

(3) 在继续给予本药物时，由于可能出现无必要继续用药或患者出现因不利于健康、合并感染等而没有效果之类令人不满意的情况，故除了要留意食物摄入量、血糖值以及有无感染症状外，还要不断关心可否继续用药以及用药量、药物的选择等情况。

(4) 本药物具有促进胰岛素迅速分泌的作用。该作用点与磺酰脲类制剂相同，但由于尚未确认它与硫酰脲类制剂的相加或相乘的临床效果及安全性，故不能与磺酰脲类药物配伍使用。

(5) 关于与α-葡糖苷酶阻滞剂、胰岛素阻滞性改善剂以及双胍类药物等配伍问题，尚未确立其有效性和安全性。

(6) 本品能有效地抑制进食后的血糖上升，故本药物应该在每次即将进食前(5分钟以内)服用。在进食后服用，若未能得到迅速吸收，则效果将降低。另外，有报告说在餐前30分钟服药的情况下，餐前15分钟时的血中胰岛素值上升，进餐开始时的血糖值下降。因此，在进餐开始前有诱发低血糖的可能

(7) 在实施糖尿病食物疗法和运动疗法基础上，空腹血糖为126毫克/ dL以上，或进食后1小时及2小时的血糖值超过200毫克/ dL的患者，限制使用本品。

Information on Glufast

Glufast is a drug for the treatment of type 2 diabetes .Glufast is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Glufast belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.

Additional information about Glufast Glufast Indication: For the treatment of type 2 diabetes. Mechanism Of Action: Glufast is a novel antidiabetic agent for the treatment of type-2 diabetes mellitus. Its chemical structure is similar to that of sulphonylureas. Glufast exerts a hypoglycaemic effect with rapid onset and short duration of action, by transiently increasing insulin secretion. Glufast is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Glufast may also activate ryanodine receptors.

New Product GLUFAST for the Treatment of Type II Diabetes Glufast, which is close to market is an insulin secretagogue with a rapid onset and short duration of action, lowers post-meal glucose levels by improving the body's own ability to produce insulin. Mr. Mutsuo Kanzawa, President and Chief Executive Officer of Kissei Pharmaceutical, stated, "We are very pleased to have signed the Glufast agreement with Elixir Pharmaceuticals. Since its launch in Japan in May 2004, Glufast has steadily increased its domestic market share and attained an important position in the treatment regimen for patients with type II diabetes. In addition to Japan, the product is currently in development in China, South Korea and the Middle East as part of Kissei's program to address patient markets worldwide." Type II diabetes is a serious and debilitating disease, affecting 14 million patients in the United States alone. While there has been significant progress in the treatment of type II diabetes, there is still an enormous unmet medical need worldwide. Mr. Heiden added, "We believe that Glufast represents an important advance for physicians and their patients who are seeking optimal glucose control. The launch of Glufast in the United States will be carried out by an Elixir specialty sales force with a focus on metabolic disease, specifically targeting diabetologists and endocrinologists. Glufast, an insulin secretagogue with a rapid onset and short duration of action, lowers post-meal glucose levels by improving the body's own ability to produce insulin. Clinical data have shown that reducing post-meal glucosesurges with Glufast decreases HbA1c levels (a standard means of assessing chronic elevated blood glucose levels). Epidemiological studies have demonstrated that uncontrolled surges in post-meal glucose levels are directly associated with negative long-term health outcomes in diabetics.

Glufast is a member of the meglitinide class of compounds; two currently marketed products in this class are expected to generate over $300 million in sales in the U.S. in 2006.